Danielle Graham
Head of Fluid Biomarkers and Bioanalytics at Biogen
Cambridge, Massachusetts
Summary
Leader of fluid biomarker strategy at Biogen, focusing on development and implementation of blood and CSF biomarkers (neurofilament, phosphorylated tau, others) to support clinical trial design, patient stratification, and regulatory decision-making. biogen+2
Translational scientist with a strong academic neuroscience background who moved from doctoral and postdoctoral research into industry roles applying translational models and biomarker assays to CNS drug development. bioanalysis-zone+1
Active contributor to major biomarker-driven clinical programs and trials (including work related to tofersen and the ATLAS presymptomatic design), helping to operationalize neurofilament and other fluid biomarkers as endpoints and trial-enrichment tools. nih+2
Public-facing communicator and conference speaker on biomarkers and neurodegenerative disease, presenting on topics ranging from tau biomarker development to quantitative fluid biomarkers for precision trials. alzheimers-parkinsons-summit+2
Work
Education
Projects
Writing
Biomarker development for the tau therapeutic landscape
January 1, 2025Review/perspective on the need for tau-specific biomarkers to support development of tau-targeting therapeutics, and exploratory biomarker results from BIIB080 (tau-targeting antisense oligonucleotide) clinical studies.
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
January 1, 2022Publication describing the design and biomarker-driven rationale for the ATLAS trial, including use of plasma neurofilament light as an early marker for phenoconversion and trial enrollment criteria; lists Danielle Graham among the co-authors/contributors from Biogen.
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
January 1, 2020Multi-cohort study evaluating neurofilament light chain as a biomarker in Parkinson's disease; Danielle Graham is listed among contributors affiliated with Biogen's biomarker groups.